Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Ferritin in glioblastoma.

Jaksch-Bogensperger H, Spiegl-Kreinecker S, Arosio P, Eckl P, Golaszewski S, Ebner Y, Al-Schameri R, Strasser P, Weis S, Bresgen N.

Br J Cancer. 2020 Mar 23. doi: 10.1038/s41416-020-0808-8. [Epub ahead of print]

PMID:
32203223
2.

Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis.

Mirian C, Duun-Henriksen AK, Juratli T, Sahm F, Spiegl-Kreinecker S, Peyre M, Biczok A, Tonn JC, Goutagny S, Bertero L, Maier AD, Møller Pedersen M, Law I, Broholm H, Cahill DP, Brastianos P, Poulsgaard L, Fugleholm K, Ziebell M, Munch T, Mathiesen T.

J Neurol Neurosurg Psychiatry. 2020 Apr;91(4):378-387. doi: 10.1136/jnnp-2019-322257. Epub 2020 Feb 10. Review.

PMID:
32041819
3.

Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors.

Erhart F, Hackl M, Hahne H, Buchroithner J, Meng C, Klingenbrunner S, Reitermaier R, Fischhuber K, Skalicky S, Berger W, Spiegl-Kreinecker S, Lötsch D, Ricken G, Kuster B, Wöhrer A, Widhalm G, Hainfellner J, Felzmann T, Dohnal AM, Marosi C, Visus C.

NPJ Vaccines. 2020 Jan 16;5:5. doi: 10.1038/s41541-019-0149-x. eCollection 2020.

4.

Long interspersed element-1 ribonucleoprotein particles protect telomeric ends in alternative lengthening of telomeres dependent cells.

Aschacher T, Wolf B, Aschacher O, Enzmann F, Laszlo V, Messner B, Türkcan A, Weis S, Spiegl-Kreinecker S, Holzmann K, Laufer G, Ehrlich M, Bergmann M.

Neoplasia. 2019 Dec 14;22(2):61-75. doi: 10.1016/j.neo.2019.11.002. [Epub ahead of print]

5.

Risks and Benefits of Glioblastoma Resection in Older Adults: A Retrospective Austrian Multicenter Study.

Schwartz C, Romagna A, Stefanits H, Zimmermann G, Ladisich B, Geiger P, Rechberger J, Winkler S, Weiss L, Fastner G, Trinka E, Weis S, Spiegl-Kreinecker S, Steinbacher J, McCoy M, Johannes T, Gruber A, Rezai Jahromi B, Niemelä M, Winkler PA, Thon N.

World Neurosurg. 2020 Jan;133:e583-e591. doi: 10.1016/j.wneu.2019.09.097. Epub 2019 Sep 24.

PMID:
31561040
6.

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma.

Gabler L, Lötsch D, Kirchhofer D, van Schoonhoven S, Schmidt HM, Mayr L, Pirker C, Neumayer K, Dinhof C, Kastler L, Azizi AA, Dorfer C, Czech T, Haberler C, Peyrl A, Kumar R, Slavc I, Spiegl-Kreinecker S, Gojo J, Berger W.

Acta Neuropathol Commun. 2019 Aug 7;7(1):128. doi: 10.1186/s40478-019-0775-6.

7.

Spheroid glioblastoma culture conditions as antigen source for dendritic cell-based immunotherapy: spheroid proteins are survival-relevant targets but can impair immunogenic interferon γ production.

Erhart F, Weiss T, Klingenbrunner S, Fischhuber K, Reitermaier R, Halfmann A, Blauensteiner B, Lötsch D, Spiegl-Kreinecker S, Berger W, Sialana FJ, Lubec G, Felzmann T, Dohnal A, Visus C.

Cytotherapy. 2019 Jun;21(6):643-658. doi: 10.1016/j.jcyt.2019.03.002. Epub 2019 Apr 8.

PMID:
30975602
8.

Gliomasphere marker combinatorics: multidimensional flow cytometry detects CD44+/CD133+/ITGA6+/CD36+ signature.

Erhart F, Blauensteiner B, Zirkovits G, Printz D, Soukup K, Klingenbrunner S, Fischhuber K, Reitermaier R, Halfmann A, Lötsch D, Spiegl-Kreinecker S, Berger W, Visus C, Dohnal A.

J Cell Mol Med. 2019 Jan;23(1):281-292. doi: 10.1111/jcmm.13927. Epub 2018 Nov 22.

9.

Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial.

Buchroithner J, Erhart F, Pichler J, Widhalm G, Preusser M, Stockhammer G, Nowosielski M, Iglseder S, Freyschlag CF, Oberndorfer S, Bordihn K, von Campe G, Hoffermann M, Ruckser R, Rössler K, Spiegl-Kreinecker S, Fischer MB, Czech T, Visus C, Krumpl G, Felzmann T, Marosi C.

Cancers (Basel). 2018 Oct 5;10(10). pii: E372. doi: 10.3390/cancers10100372.

10.

TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.

Spiegl-Kreinecker S, Lötsch D, Neumayer K, Kastler L, Gojo J, Pirker C, Pichler J, Weis S, Kumar R, Webersinke G, Gruber A, Berger W.

Neuro Oncol. 2018 Nov 12;20(12):1584-1593. doi: 10.1093/neuonc/noy104.

11.

Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.

Gojo J, Lötsch D, Spiegl-Kreinecker S, Pajtler KW, Neumayer K, Korbel P, Araki A, Brandstetter A, Mohr T, Hovestadt V, Chavez L, Kirchhofer D, Ricken G, Stefanits H, Korshunov A, Pfister SM, Dieckmann K, Azizi AA, Czech T, Filipits M, Kool M, Peyrl A, Slavc I, Berger W, Haberler C.

Neuro Oncol. 2017 Sep 1;19(9):1183-1194. doi: 10.1093/neuonc/nox027.

12.

Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.

Spiegl-Kreinecker S, Lötsch D, Ghanim B, Pirker C, Mohr T, Laaber M, Weis S, Olschowski A, Webersinke G, Pichler J, Berger W.

Neuro Oncol. 2015 Sep;17(9):1231-40. doi: 10.1093/neuonc/nov010. Epub 2015 Feb 13.

13.

[Corrigendum] Temozolomide-induced modification of the CXC chemokine network in experimental gliomas.

Bruyère C, Mijatovic T, Lonez C, Spiegl-Kreinecker S, Berger W, Kast R, Ruysschaert JM, Kiss R, Lefranc F.

Int J Oncol. 2013 Dec 9. doi: 10.3892/ijo.2013.2212. [Epub ahead of print]

PMID:
24337097
14.

Major vault protein supports glioblastoma survival and migration by upregulating the EGFR/PI3K signalling axis.

Lötsch D, Steiner E, Holzmann K, Spiegl-Kreinecker S, Pirker C, Hlavaty J, Petznek H, Hegedus B, Garay T, Mohr T, Sommergruber W, Grusch M, Berger W.

Oncotarget. 2013 Nov;4(11):1904-18.

15.

Ophiobolin A induces paraptosis-like cell death in human glioblastoma cells by decreasing BKCa channel activity.

Bury M, Girault A, Mégalizzi V, Spiegl-Kreinecker S, Mathieu V, Berger W, Evidente A, Kornienko A, Gailly P, Vandier C, Kiss R.

Cell Death Dis. 2013 Mar 28;4:e561. doi: 10.1038/cddis.2013.85.

16.

Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age.

Lötsch D, Ghanim B, Laaber M, Wurm G, Weis S, Lenz S, Webersinke G, Pichler J, Berger W, Spiegl-Kreinecker S.

Neuro Oncol. 2013 Apr;15(4):423-32. doi: 10.1093/neuonc/nos329. Epub 2013 Feb 7.

17.

Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation.

Mathieu V, Pirker C, Schmidt WM, Spiegl-Kreinecker S, Lötsch D, Heffeter P, Hegedus B, Grusch M, Kiss R, Berger W.

Oncotarget. 2012 Apr;3(4):399-413.

18.

Trabectedin has promising antineoplastic activity in high-grade meningioma.

Preusser M, Spiegl-Kreinecker S, Lötsch D, Wöhrer A, Schmook M, Dieckmann K, Saringer W, Marosi C, Berger W.

Cancer. 2012 Oct 15;118(20):5038-49. doi: 10.1002/cncr.27460. Epub 2012 Mar 5.

19.

Stable protein expression in mammalian cells using baculoviruses.

Lackner A, Kreidl E, Peter-Vörösmarty B, Spiegl-Kreinecker S, Berger W, Grusch M.

Methods Mol Biol. 2012;801:75-92. doi: 10.1007/978-1-61779-352-3_6.

PMID:
21987248
20.

Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.

Metzner T, Bedeir A, Held G, Peter-Vörösmarty B, Ghassemi S, Heinzle C, Spiegl-Kreinecker S, Marian B, Holzmann K, Grasl-Kraupp B, Pirker C, Micksche M, Berger W, Heffeter P, Grusch M.

J Invest Dermatol. 2011 Oct;131(10):2087-95. doi: 10.1038/jid.2011.177. Epub 2011 Jul 14.

21.

Temozolomide-induced modification of the CXC chemokine network in experimental gliomas.

Bruyère C, Mijatovic T, Lonez C, Spiegl-Kreinecker S, Berger W, Kast RE, Ruysschaert JM, Kiss R, Lefranc F.

Int J Oncol. 2011 May;38(5):1453-64. doi: 10.3892/ijo.2011.964. Epub 2011 Mar 8.

PMID:
21399866
22.

Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465.

Pirker C, Lötsch D, Spiegl-Kreinecker S, Jantscher F, Sutterlüty H, Micksche M, Grusch M, Berger W.

Exp Dermatol. 2010 Dec;19(12):1040-7. doi: 10.1111/j.1600-0625.2010.01182.x.

PMID:
21087322
23.

Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration.

Sonvilla G, Allerstorfer S, Heinzle C, Stättner S, Karner J, Klimpfinger M, Wrba F, Fischer H, Gauglhofer C, Spiegl-Kreinecker S, Grasl-Kraupp B, Holzmann K, Grusch M, Berger W, Marian B.

Br J Cancer. 2010 Mar 30;102(7):1145-56. doi: 10.1038/sj.bjc.6605596. Epub 2010 Mar 16.

24.

O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.

Spiegl-Kreinecker S, Pirker C, Filipits M, Lötsch D, Buchroithner J, Pichler J, Silye R, Weis S, Micksche M, Fischer J, Berger W.

Neuro Oncol. 2010 Jan;12(1):28-36. doi: 10.1093/neuonc/nop003. Epub 2009 Oct 15.

25.

Screening of anti-glioma effects induced by sigma-1 receptor ligands: potential new use for old anti-psychiatric medicines.

Mégalizzi V, Decaestecker C, Debeir O, Spiegl-Kreinecker S, Berger W, Lefranc F, Kast RE, Kiss R.

Eur J Cancer. 2009 Nov;45(16):2893-905. doi: 10.1016/j.ejca.2009.07.011. Epub 2009 Aug 11.

PMID:
19679463
26.

Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells.

Lefranc F, Sauvage S, Van Goietsenoven G, Mégalizzi V, Lamoral-Theys D, Debeir O, Spiegl-Kreinecker S, Berger W, Mathieu V, Decaestecker C, Kiss R.

Mol Cancer Ther. 2009 Jul;8(7):1739-50. doi: 10.1158/1535-7163.MCT-08-0932. Epub 2009 Jun 16. Erratum in: Mol Cancer Ther. 2012 May;11(5):1216-7.

27.

Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression.

Le Mercier M, Fortin S, Mathieu V, Roland I, Spiegl-Kreinecker S, Haibe-Kains B, Bontempi G, Decaestecker C, Berger W, Lefranc F, Kiss R.

Neoplasia. 2009 May;11(5):485-96.

28.

Structure-activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents.

Ingrassia L, Lefranc F, Dewelle J, Pottier L, Mathieu V, Spiegl-Kreinecker S, Sauvage S, El Yazidi M, Dehoux M, Berger W, Van Quaquebeke E, Kiss R.

J Med Chem. 2009 Feb 26;52(4):1100-14. doi: 10.1021/jm8013585.

PMID:
19199649
29.

Galectin-1 is implicated in the protein kinase C epsilon/vimentin-controlled trafficking of integrin-beta1 in glioblastoma cells.

Fortin S, Le Mercier M, Camby I, Spiegl-Kreinecker S, Berger W, Lefranc F, Kiss R.

Brain Pathol. 2010 Jan;20(1):39-49. doi: 10.1111/j.1750-3639.2008.00227.x. Epub 2009 Oct 8.

30.

A bicistronic baculovirus vector for transient and stable protein expression in mammalian cells.

Lackner A, Genta K, Koppensteiner H, Herbacek I, Holzmann K, Spiegl-Kreinecker S, Berger W, Grusch M.

Anal Biochem. 2008 Sep 1;380(1):146-8. doi: 10.1016/j.ab.2008.05.020. Epub 2008 May 22.

PMID:
18541133
31.

FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities.

Allerstorfer S, Sonvilla G, Fischer H, Spiegl-Kreinecker S, Gauglhofer C, Setinek U, Czech T, Marosi C, Buchroithner J, Pichler J, Silye R, Mohr T, Holzmann K, Grasl-Kraupp B, Marian B, Grusch M, Fischer J, Micksche M, Berger W.

Oncogene. 2008 Jul 10;27(30):4180-90. doi: 10.1038/onc.2008.61. Epub 2008 Mar 24.

32.

Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma.

Spiegl-Kreinecker S, Pirker C, Marosi C, Buchroithner J, Pichler J, Silye R, Fischer J, Micksche M, Berger W.

Br J Cancer. 2007 Mar 26;96(6):960-9. Epub 2007 Mar 6.

33.

Whole genome amplification for CGH analysis: Linker-adapter PCR as the method of choice for difficult and limited samples.

Pirker C, Raidl M, Steiner E, Elbling L, Holzmann K, Spiegl-Kreinecker S, Aubele M, Grasl-Kraupp B, Marosi C, Micksche M, Berger W.

Cytometry A. 2004 Sep;61(1):26-34.

34.

Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes.

Pirker C, Holzmann K, Spiegl-Kreinecker S, Elbling L, Thallinger C, Pehamberger H, Micksche M, Berger W.

Melanoma Res. 2003 Oct;13(5):483-92.

PMID:
14512790
35.

Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes.

Spiegl-Kreinecker S, Buchroithner J, Elbling L, Steiner E, Wurm G, Bodenteich A, Fischer J, Micksche M, Berger W.

J Neurooncol. 2002 Mar;57(1):27-36.

PMID:
12125964
36.

Overexpression of the human major vault protein in astrocytic brain tumor cells.

Berger W, Spiegl-Kreinecker S, Buchroithner J, Elbling L, Pirker C, Fischer J, Micksche M.

Int J Cancer. 2001 Nov 1;94(3):377-82.

Supplemental Content

Loading ...
Support Center